Impact of bone marker feedback on adherence to once monthly ibandronate for osteoporosis among Asian postmenopausal women

International Journal of Rheumatic Diseases

Volumn 12, Issue 3, 2009, Pages 216-224

  Kung, Annie Wai Chee ^a   Rachman, Ichramsjah A ^b   Adam, John M F ^c   Roeshadi, Djoko ^d   Torralba, Tito ^e   Navarra, Sandra ^e   Gamilla, Zayda ^e   Cañete, Arthur ^f   de la Rosa, Miles ^f   Tsai, Keh Sung ^g   Lin, Hsiao Yi ^h   Soong, Yung Kuei ⁱ   Lan, Joung Liang ^j   Hsu, Horng Chaung ^k   Tu, Shih Te ^l   Lin, Ruey Mo ^m   Yuktanandana, Pongsak ⁿ   Songpatanasilp, Thawee ^o   Ngarmukos, Srihatach ⁿ   Soontrapa, Sugree ^p   Soontrapa, Suppasin ^p   Rojanasthien, Sattaya ^q   Luevitoonvechkij, Sirichai ^q   Leerapan, Taninnit ^q   Albert, Adelin ^r   Vanbelle, Sophie ^r   more..

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF INDONESIA   (Indonesia)

^c Akademis Jaury Hospital   (Indonesia)

^d AIRLANGGA UNIVERSITY   (Indonesia)

^e UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^f Philippine Heart Centre   (Philippines)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

ⁱ CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^j TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^k CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^l CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^m NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁿ KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^o Phramongkutklao Military Hospital   (Thailand)

^p KHON KAEN UNIVERSITY   (Thailand)

^q CHIANG MAI UNIVERSITY   (Thailand)

^r UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

Adherence; Bone marker; Compliance; Feedback; Ibandronate; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; IBANDRONIC ACID;

AGED; ARTICLE; ASIAN; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; ILEUS; INFECTION; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SATISFACTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPATHY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT COMPLIANCE; PATIENT SATISFACTION;

EID: 69149106711     PISSN: 17561841     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2009.01413.x     Document Type: Article

References (27)

1. Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359, 1761-7.
2. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359, 2018-26.
3. Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15, M406. (Abstract).
4. Finigan J, Bainbridge PR, Eastell R (2001) Adherence to osteoporosis therapies. Osteoporos Int 12, S48-9, P110 (Abstract).
5. Caro J, Ishak K, Huybrechts K, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15, 1003-8.
6. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2003) Clinical and economic impact of adherence to osteoporosis medication. Osteoporos Int 14, PL6. (Abstract).
7. Sambrook PN, Rodriguez JP, Wasnich RD, et al. (2004) Alendronate in the prevention of osteoporosis: 7-year follow-up. Osteoporos Int 15, 483-8.
8. Bone HG, Hosking D, Devogelaer JP, et al. (2004) Ten years'experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350, 1189-99.
9. Sorensen OH, Crawford GM, Mulder H, et al. (2003) Long-term efficacy of risedronate: A 5-year placebo controlled clinical experience. Bone 32, 120-6.
10. Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14, 259-62.
11. World Health Organization (2003) Adherence to long-term therapies. Evidence for action. WHO/MNC/03.01.
12. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of Biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11, S2-17.
13. Looker AC, Bauer DC, Chesnut CH III, et al. (2000) Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11, 467-80.
14. Hannon R, Eastell R (2000) Preanalytical variability of biochemical markers of bone turnover. Osteoporos Int 11, S30-44.
15. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30, 886-90.
16. Flood EM, Beusterien KM, Green H, et al. (2006) Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4, 42.
17. F Hoffmann-La Roche Ltd. MEDTAP Institute at United Biosource Corp. OPPS Scoring guideline, Version 2.0 as of 08.09.05.
18. World Health Organization (2003) Prevention and management of osteoporosis. World Health Organ Tech Rep Ser 921, 1-164.
19. Reginster JY, Lecart MP (2004) Treatment of osteoporosis with bisphosphonates - do compliance and persistence matter? Business Briefing: Long-term Healthcare 1-9.
20. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48, 271-87.
21. Solomon DH, Avorn J, Katz JN, et al. (2005) Compliance with osteoporosis medications. Arch Intern Med 165, 2414-9.
22. Clowes JA, Peel NFA, Eastell R (2004) The impact of monitoring on adherence and persistence with anti-resorptive treatment for post-menopausal osteoporosis: A randomized controlled trial. J Clin Endocrinol Metab 89, 1117-23.
23. Delmas PD, Vrijens B, Eastell R, et al. (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92, 1296-304.
24. McHorney CA, Schousboe JT, Cline RR, Weiss TW (2007) The impact of osteoprosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates. Curr Med Res Opin 23, 3137-52.
25. Bonnick SL, Martens M, Civitelli R, Friend K, Silverman S (2007) Women with postmenopausal osteoporosis or osteopenia previously receiving weekly alendronate or risedronate are more satisfied with monthly ibandronate. Calcif Tissue Int 80(Suppl. 1), s118 (Abstract P308-T).
26. Emkey R, Koltun W, Beusterien K, et al. (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Boniva Alendronate Trial in Osteoporosis. Curr Med Res Opin 21, 1895-903.
27. Miller PD, McClung MR, Macovei L, et al. (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20, 1315-22.